(Q43010565)

12 November 2017

title

Efficacy and safety of sorafenib in advanced hepatocellular carcinoma under daily practice conditions (English)

1 reference

12 November 2017

main subject

hepatocellular carcinoma

1 reference

6

Vogl TJ

1 reference

12 November 2017

Welker MW

1

1 reference

12 November 2017

Lubomierski N

2

1 reference

12 November 2017

Gog C

3

1 reference

12 November 2017

Herrmann E

4

1 reference

12 November 2017

Engels K

5

1 reference

12 November 2017

Bechstein WO

7

1 reference

12 November 2017

Zeuzem S

8

1 reference

12 November 2017

Trojan J

9

1 reference

12 November 2017

publication date

1 June 2010

1 reference

12 November 2017

published in

Journal of Chemotherapy

1 reference

12 November 2017

volume

22

1 reference

12 November 2017

issue

3

1 reference

12 November 2017

page(s)

205-211

1 reference

Global cancer statistics, 2002

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.3.205

Serum markers of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.3.205

The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.3.205

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.3.205

Review on transarterial chemoembolization in hepatocellular carcinoma: palliative, combined, neoadjuvant, bridging, and symptomatic indications

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.3.205

Prognosis of hepatocellular carcinoma: the BCLC staging classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.3.205

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.3.205

New therapies for hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.3.205

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.3.205

Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.3.205

Hepatocellular carcinoma 2009 and beyond: from the surveillance to molecular targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.3.205

Design and endpoints of clinical trials in hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.3.205

Image-guided tumor ablation: proposal for standardization of terms and reporting criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.3.205

Hepatocellular carcinoma in southern Germany: epidemiological and clinicopathological characteristics and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.3.205

Prognosis of a large cohort of patients with hepatocellular carcinoma in a single European centre

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.3.205

A model to predict survival in patients with end-stage liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.3.205

MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: a European study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.3.205

Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a Hepatitis B virus-endemic area

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.3.205

Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.3.205

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.3.205

Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.3.205

Sorafenib: a review of its use in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.3.205

Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.3.205

Recurrences of hepatocellular carcinoma following initial remission by transcatheter arterial chemoembolization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.3.205

10.1179/JOC.2010.22.3.205

21 January 2018

Identifiers

DOI

1 reference

release_mujk2chu6neivmjh3pn6f73kki

12 November 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/mujk2chu6neivmjh3pn6f73kki

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference